4Hooghe R, Dogusan Z, Martens N, et al. [J].Lupus, 2001,10(10) :719-727.
5Lavalle C, Loyo E, Paniagua R, et al. [J]. J Rheumatol, 1987, 14(2) :268-272.
6Vera-Lastra O, Jara LJ, Espinoza LR. [J]. Autoimmun Rev, 2002,1 (6) :360-364.
7Peeva E, Grimaldi C, Spatz L, et al. [J]. J Clin Invest, 2000,106( 11 ) : 1373-1379.
8McMurray RW. [J]. Lupus, 2001,10(10) :742-747.
9Vera-Lastra O, Mendez C, Jara LJ, et al. [J]. J Rheumatol, 2003,30(10) :2140-2146.
10Moszkorzova L, Lacinova Z, Marek J, et al. [ J ].Clin Exp Rheumatol, 2002,20(6) :807-812.
同被引文献8
1Ran KN,Van Thiel DH.Pancreatic stone protein:what is it and what do it do[J].Dig Dis Sci,1991,36(10):1505.
2Jara LJ,Gomez-Sanchez C,Silveira LH,et al.Hyperprolactinemia in systemic lupus erythematosus association with disease acivity[J].Am J Med Sci,1992,303(3):222.
3Besedovsky H.Network of immune-neuroendocrine interactions[J].Clin Exp Immunol,1977,27 (1):1-12.
4Jara L,Vera L,Mirarda J,et al.Prolactin in human systemic lupus erythematosus[J].Lupus,2001,10(7):748-756.
